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Abstract
Rare variation in TREM2 has been associated with greater risk for Alzheimer’s disease (AD). TREM2 encodes a cell
surface receptor expressed on microglia and related cells, and the R47H variant associated with AD appears to
affect the ability of TREM2 to bind extracellular ligands. In addition, other rare TREM2 mutations causing early-onset
neurodegeneration are thought to impair cell surface expression. Using a sequence kernel association (SKAT)
analysis in two independent AD cohorts, we found significant enrichment of rare TREM2 variants not previously
characterized at the protein level. Heterologous expression of the identified variants showed that novel variants
S31F and R47C displayed significantly reduced cell surface expression. In addition, we identified rare variant R136Q
in a patient with language-predominant AD that also showed impaired surface expression. The results suggest rare
TREM2 variants enriched in AD may be associated with altered TREM2 function and that AD risk may be conferred,
in part, from altered TREM2 surface expression.
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Introduction
Alzheimer’s disease (AD) is a common neurodegenera-
tive disorder that occurs in older adults. Clinically, AD is
characterized by a decline in cognitive function includ-
ing memory, language, and/or visuospatial abilities. Ag-
gregation of amyloid-β and hyperphosphorylated tau,
which result in the formation of plaques and neurofibril-
lary tangles, respectively, represent the pathological hall-
marks of AD. In addition to factors contributing to
accumulation of amyloid and tau, changes in immune
function resulting in increased inflammation are thought
to contribute to disease pathogenesis and progression.
Common variants like APOE ε4 are the best character-
ized genetic risk factors associated with AD. However,
rare genetic variation, which occurs at <1 % minor allele
frequency (MAF) in a given population, is becoming in-
creasingly appreciated for its contribution to neurode-
generative disease. These infrequent variants often have
more potent biological effects and can occur in genes
encoding proteins intimately linked to underlying pro-
tein pathology. Rare variants that confer both risk for
[1–5] and protection from [6, 7] different forms of neu-
rodegeneration have been identified, but, due to their
low MAF, most of these studies required very large co-
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TREM2 is a widely studied gene known to harbor rare
variation that can either cause or contribute to risk for
distinct neurodegenerative diseases. Homozygous or com-
pound heterozygous mutations in TREM2 are known to
cause Nasu-Hakola disease (NHD) or an early-onset fron-
totemporal dementia (FTD)-like syndrome, while rare
variation in TREM2 increases risk for AD, and may also
increase risk for FTD, Parkinson’s disease, and amyo-
trophic lateral sclerosis [8–10]. In the brain, TREM2 is an
innate immune system receptor expressed primarily on
microglia [11]. It has been implicated in sensing damage
signals, promoting microglial survival, and regulating cen-
tral nervous system inflammation [12–14]. In particular,
the R47H variant in TREM2 has been associated with AD
risk in populations of European descent [4, 5], and is
thought to alter microglial function [13, 15]. Recent evi-
dence suggests that the R47H variant acts by altering
TREM2’s ability to bind lipoproteins and apolipoproteins,
which may ultimately prevent microglia from efficiently
absorbing amyloid-β-lipoprotein complexes [16].
Assessment of mutation burden can alleviate require-
ments for large cohorts by accounting for the overall risk
contribution of rare and even unique variation observed in
the same gene but in different individuals. Gene-based ana-
lysis offers the unique advantage of weighing the combined
effects of multiple variants (common and/or rare) into a
single statistical measure of disease risk [17, 18]. Combining
rare variants into a single analysis increases power to detect
disease-associated risk in a gene using a relatively small co-
hort [17]. Furthermore, characterizing distinct rare variants
occurring within the same functional domain of a particular
protein may offer additional insight into shared pathogenic
mechanisms. Of the available gene-based tests, the se-
quence kernel association test (SKAT) and its variants have
proven reliable under multiple cohort sizes and have high
mean power when compared to other tests [18–20].
In this study, we assessed deep sequencing data from over
150 genes previously linked to neurodegenerative, neuro-
psychiatric, and neurodevelopmental phenotypes for rare
variant burden contributing to AD. We confirmed that mu-
tation burden in TREM2 is robustly associated with AD
risk in two independent cohorts. We then characterized
biochemically a subset of rare TREM2 variants to test
whether they alter cell surface expression as a means of
assessing their functional significance. Our analysis showed
that several of the rare variants identified in AD indeed sig-
nificantly reduced overall expression as well as cell surface
expression of TREM2, suggesting that these variants may
reduce protein function and contribute to disease risk.
Materials and methods
Participants and clinical assessment
For the discovery genetic analysis, 115 males and 161 fe-
males were evaluated at the University of California, San
Francisco Memory and Aging Center (UCSF MAC), and
had genetic data available for analysis. All participants
underwent clinical assessment with an in-person visit at
the UCSF MAC that included a neurologic exam, cogni-
tive assessment [21, 22] and medical history. Each par-
ticipant’s study partner was also interviewed regarding
functional abilities. A multidisciplinary team composed
of a neurologist, neuropsychologist, and nurse then
established clinical diagnoses for cases according to con-
sensus criteria for AD and its subtypes [23, 24]. All
healthy controls underwent a similar assessment, includ-
ing study partner interview, and a consensus team of cli-
nicians then established clinical diagnosis of cognitively
normal. Controls in this study had Mini-Mental State
Exam (MMSE) [25] scores ≥26 or a Clinical Dementia
Rating Scale (CDR) [26] of 0, no participant or inform-
ant report of cognitive concerns or decline in the prior
year, and no evidence from clinical visit suggesting a
neurodegenerative disorder (per team neurologist). De-
tailed demographic information is included in Table 1.
Individuals harboring a known disease mutation or with
a family history of neurodegeneration were excluded
from the study.
Replication analysis was performed on samples from
the case–control component of the Alzheimer’s Disease
Sequencing Project (ADSP), a Presidential Initiative
established to identify new genes and alleles contributing
to AD risk, AD protection, and targets for new AD ther-
apies, particularly for late-onset AD. The discovery
phase of this project generated whole exome sequencing
(WES) data for 10,061 unrelated individuals (N = 5,096
cases, N = 4,965 controls) from the Alzheimer’s Disease
Genetics Consortium and the Cohorts for Heart Aging
Research in Genomic Epidemiology consortia, of which
5,560 are included in the replication analysis (see Table 1
for cohort demographics). All cases met criteria for
probable or definite AD based on clinical assessment, or
had neuropathological features of AD upon brain aut-
opsy. Pathological staging was made according to criteria
set forth in Braak and Braak (1995) [27]. Cases received
a Braak staging score greater than or equal to 3. All con-
trols were clinically assessed for dementia or had an ab-
sence of neuropathological AD features upon autopsy
(Braak score of 2 or less). Individuals carrying a known
disease mutation were excluded from the analyses. All
sample phenotype and demographic data were obtained
from dbGAP (study accession phs000572.v6.p4; table ac-
cession pht004306.v4.p4.c1).
All participants in both analyses were unrelated white
individuals (confirmed by identity-by-descent testing in
the replication analysis or self-described for those with-
out GWAS data available). Non-Caucasian individuals
were excluded due to the insufficient number of partici-
pants and potential for confounding background
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genetics. All aspects of the study were approved by the
UCSF Institutional Review Board and written informed
consent was obtained from all participants and surro-
gates (as per UCSF Institutional Review Board protocol).
Sequencing
The UCSF cohort was screened using targeted sequencing
of more than 150 RefSeq genes previously implicated in
neurodegenerative dementia, including the most common
causative genes for Mendelian forms of AD and FTD.
Exonic regions for these genes were captured using a
custom-designed Nimblegen SeqCap EZ Choice (Roche)
library and sequenced on an Illumina HiSeq2500 at the
UCLA Neuroscience Genomics Core (Los Angeles, CA).
Sequence reads were mapped to the GRCh37/hg19 refer-
ence genome and variants were interactively joint-called
with GATK according to GATK Best Practices recom-
mendations (https://www.broadinstitute.org/gatk/ [28]).
ADSP samples underwent WES at one of three
NHGRI funded large-scale sequencing centers at Baylor,
the Broad Institute, or Washington University. Whole
exome capture was performed using either the Illumina
Rapid Capture Exome kit or VCRome v2.1 kit (Nimblegen),
and paired-end reads were generated using an Illumina
HiSeq 2000. Sequence reads were aligned to the GRCh37
reference genome using the Burrows-Wheeler aligner [29],
and variants were jointly called across the entire cohort
using Atlas V2 software (Baylor) or GATK (Broad). Variants
underwent pipeline-specific quality control prior to mer-
ging the variants that were concordant between the two
sets of variants. The ADSP also performed initial quality
control checks on sample information, phenotypes, and
genotype data to ensure that these data were of high quality
and suitable for downstream analysis.
Quality control and post-processing
After joint-calling, variants were filtered according to
previously established criteria [30]. Briefly, we kept joint-
called variants with genotype quality (GQ) scores greater
than 30 and read depth (DP) scores greater than 20. The
resulting file was annotated with gene names using the
Variant Effect Predictor in Ensembl. The predicted effect
of each variant were determined using PolyPhen and
SIFT. Prior to analysis, we used PLINK [31] to remove
individuals with genotyping rates below 95 %, SNPs (sin-
gle nucleotide polymorphisms) with genotyping rates
below 95, and SNPs with a MAF greater than 1 %. Gene
SNP sets were created from exonic SNPs classified as
missense and nonsense variants. For our replication ana-
lysis, we created SNP sets using the same genes that
were available for study in our discovery cohort.
Genetic analyses
Following previously published criteria [18], we limited
our analyses to gene SNP sets with 4 or more SNPs
available. For our discovery analysis we conducted a
SKAT analysis in the amnestic AD cohort from UCSF.
Our replication analysis in the ADSP amnestic AD co-
hort used the same testing parameters and techniques.
We repeated the aforementioned analysis in subset of
Table 1 Study participant characteristics
Cohort Variable AD Control P-value
Discovery (UCSF) N 31 245
Age at Onset / First Visit 77.8 ± 4.5 68.5 ± 8.5 p < 0.001
Sex (M / F) 16 / 15 99 / 146 0.18
Edu (Years, Mean ± SD) 17.0 ± 3.7 17.3 ± 2.1 0.45
CDR (Mean ± SD) 0.8 ± 0.3 0.0 ± 0.1 p < 0.001
MMSE (Mean ± SD) 22.2 ± 5.3 29.4 ± 0.8 p < 0.001
APOE ε4 dose (0 / 1 / 2) 9 / 17 / 5 190 / 48 / 4 p < 0.001
# Pathological Confirmed AD 12
Replication (ADSP) N 2927 2633
Age at Onset / First Visit 75.3 ± 8.4 85.5 ± 5.1 p < 0.001
Sex (M / F) 1299 / 1628 1185 / 1448 0.639334
Edu (Years, Mean ± SD) NA NA NA
CDR (Mean ± SD) NA NA NA
MMSE (Mean ± SD) NA NA NA
APOE ε4 dose (0 / 1 / 2) 1660 / 1184 / 83 2239 / 386 / 8 p < 0.001
# Pathological Confirmed AD 1057
Summary demographic, clinical, and genetic information is shown for the Discovery and Replication Cohorts. Note: three individuals in the UCSF Cohort (all
controls) do not currently have APOE ε4 genotyped. M Male, F Female, Edu Education, SD Standard Deviation, MMSE Mini Mental State Examination, NA
Not Available
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the ADSP cohort that had pathologically confirmed AD.
Finally, to test whether rare variation in TREM2 is associ-
ated with clinically heterogeneous AD, we ran a SKAT
analysis in a subset of the cohort which included amnestic
AD, early-onset AD, executive (frontal) AD, and the logo-
penic variant of primary progressive aphasia (lvPPA).
Antibodies
The HA.11 monoclonal antibody used to detect HA-
TREM2 was from Covance, and the clathrin heavy
chain monoclonal antibody was from BD Transduction
Laboratories.
Molecular biology
The human TREM2 cDNA was obtained from R&D
Systems, amplified by PCR and inserted into the pEGFP-
N1 vector after first removing the EGFP coding se-
quence. To facilitate detection of TREM2, an HA
epitope tag and linker sequence identical to that used in
Kleinberger et al. [14], were inserted after the TREM2
signal peptide using the Phusion high-fidelity DNA poly-
merase (NEB) system for site-directed mutagenesis. All
TREM2 variants were similarly generated using Phusion,
with the HA-TREM2 construct serving as template
DNA. All constructs were verified by sequencing at the
UC Berkeley DNA Sequencing Facility.
Cell culture
HEK-293T cells were maintained at the UC Berkeley Cell
Culture Facility under standard conditions. Cells were
transiently transfected using Lipofectamine 2000 (Ther-
moFisher) according to the manufacturer’s instructions.
Culture medium was typically changed 4 h after trans-
fection, and experiments were carried out the following
day.
Immunoblotting
Cells were harvested on ice by washing with cold PBS
followed by lysing in a buffer containing 100 mM NaCl,
10 mM Tris-Cl, pH 7.6, 1 % (v/v) Triton X-100 and
Complete protease inhibitor cocktail (Roche). Triton-
insoluble material was sedimented by centrifugation at
20,000 g for 10 min at 4 °C. Supernatants were mixed
with 5X SDS-PAGE sample buffer supplemented with
DTT, then heated at 55 °C for 10 min prior to running
in 4–20 % acrylamide gradient gels (Life Technologies
and Bio-Rad). After SDS-PAGE, proteins were trans-
ferred onto PVDF membranes (EMD Millipore), blocked
in 5 % non-fat milk (dissolved in PBS containing 0.1 %
Tween-20), and probed with HA and CHC antibodies at
1:2,500 and 1:10,000, respectively. Blots were developed
using enhanced chemiluminescence and imaged on a
ChemiDoc digital imager (Bio-Rad). Protein signals were
quantified using ImageJ (NIH). For overall TREM2
expression analysis, the TREM2 signals derived from cell
lysates were first normalized to the corresponding CHC
signal, then calculated as a fraction of the WT signal.
Cell surface biotinylation
Cell surface biotinylation was carried out in a manner
similar to that performed in Kleinberger et al., 2014.
Briefly, cells were washed at room temperature (RT)
with PBS and labeled with the EZ-Link Sulfo-NHS-SS-
Biotin reagent (ThermoFisher) at 1 mg/ml in PBS for
15 min. Cells were then placed on ice, washed with cold
Tris-buffered saline to quench the biotin reagent, then
washed with cold PBS and finally lysed and clarified as
described above. To capture biotinylated proteins, Strep-
Tactin resin (iba) was added to the clarified lysates and
the mixtures rotated at 4 °C for 1 h. The resin was then
pelleted and washed multiple times with lysis buffer.
Finally, 2X SDS-PAGE sample buffer supplemented with
DTT was added to the washed resin, and the samples
were vortexed, heated and prepared for immunoblotting
as described above. For the analysis of surface-labeled
TREM2, we quantified the entire surface-labeled signal
(including mature and immature bands) by densitometry
and normalized the signal of individual variants to the
WT signal.
Statistical analysis
We used the “SKAT” package [18] in R to conduct all
gene-based association tests. The SKAT package allows
users to conduct sequence kernel association tests,
which are powerful when a portion of the variants in a
region are noncausal or variant effects are in different
directions. All genetic analyses using in the MAC and
ADSP cohorts were completed using R.
Protein expression analyses and plots were completed
using Graphpad Prism 6 (La Jolla, CA). Protein expres-
sion differences were established with ANOVA tests. We
used the Holm-Sidak method for our post hoc testing.
Results
Cohort descriptions
Two hundred and seventy six individuals (245 healthy
controls and 31 individuals with AD) participated in this
study’s discovery analysis; 5,560 (2,633 healthy controls
and 2,927 individuals with AD) participated in this
study’s replication analysis. Detailed cohort characteris-
tics by diagnostic grouping for each cohort are provided
in Table 1. In both cohorts, there were significant differ-
ences in age by diagnostic grouping and APOE ε4 dos-
age, and no significant differences by sex. As expected,
in the discovery cohort, there were significant differ-
ences in mean CDR and MMSE score. There was no sig-
nificant difference in education in the discovery cohort.
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Rare variation in TREM2 is enriched in amnestic Alzheimer’s
disease
Discovery analysis
After quality control and annotation, 157 gene SNP
sets were identified. The identified genes are listed in
Additional file 1: List S1. Of these, 43 gene SNP sets
had 4 or more eligible SNPs and were included in the
aggregate burden analysis. The most significant gene
SNP set in our discovery analysis was TREM2 (p =
0.001). After multiple testing correction using the
Bonferroni method, the p-value for TREM2 was 0.04.
Summary data for this analysis are shown in Table 2.
The variants included in the TREM2 SNP set and
their amino acid coding changes are summarized in
Table 3. Full results for all 43 SNP sets are shown in
Additional file 1: Table S1.
Replication analysis in clinically diagnosed and
pathologically confirmed AD
We started with the same 157 genes available in the dis-
covery analysis. Of these, 65 gene SNP sets had 4 or more
eligible SNPs. The most significant gene SNP set in the
replication cohort was also TREM2 (p = 2.88x10−4). After
multiple testing correction using the Bonferroni method,
the p-value for TREM2 was 0.02. The variants included in
the TREM2 SNP set and their amino acid coding changes
are summarized in Table 3. There were 1,057 neuropatho-
logically confirmed AD cases in the ADSP cohort and we
Table 2 Aggregate variant burden analysis in discovery and replication cohorts
Cohort Gene Testable SNPs SNPs tested MAC P-value Corrected P-value
Discovery (UCSF) TREM2 19 8 10 1.00×10−3 0.04
SMG6 38 4 4 3.42×10−2 NS
ARHGAP27 17 4 6 0.1 NS
HSPA6 18 6 9 0.15 NS
LRRK2 46 9 10 0.16 NS
WDR81 28 10 12 0.2 NS
PLCD3 16 4 5 0.2 NS
MAP1B 28 7 9 0.22 NS
UBAP1 11 4 4 0.22 NS
NPEPPS 11 4 6 0.23 NS
Replication (ADSP) TREM2 41 24 330 2.88×10−4 0.02
GYPC 24 16 31 5.19×10−3 NS
UBAP2 123 72 207 0.05 NS
PACRG 20 14 93 0.06 NS
ZNF621 32 17 24 0.06 NS
EPHX2 56 38 284 0.08 NS
RPIA 28 9 11 0.09 NS
FYN 28 13 43 0.1 NS
HSPA6 25 20 89 0.11 NS
HSPA4 59 28 183 0.12 NS
Replication (ADSP - Pathology Confirmed) TREM2 41 16 192 2.11×10−4 0.01
CLU 51 19 108 2.78×10−3 NS
KIF24 136 54 243 6.00×10−3 NS
GYPC 24 8 12 0.02 NS
BIN1 61 16 41 0.03 NS
RNF19A 56 23 48 0.03 NS
MR1 43 18 106 0.04 NS
EPHX2 56 29 181 0.06 NS
RPIA 28 7 9 0.09 NS
PACRG 20 12 58 0.09 NS
Results from discovery and replication burden analyses in SKAT. Genes in bold were significant after multiple testing correction. SNP single nucleotide
polymorphism, MAC minor allele count, NS not significant
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performed an additional analysis restricted to these cases
versus all available ADSP controls. Of the 157 genes from
the discovery analysis, 61 gene SNP sets had 4 or more eli-
gible SNPs. TREM2 was also the most significant gene
SNP set in the pathology-confirmed AD replication ana-
lysis (p = 2.11×10−4). After multiple testing correction
using the Bonferroni method, the p-value for TREM2 was
0.01. Summary data for both the clinically diagnosed AD
replication cohort and pathologically diagnosed AD co-
hort are shown in Table 2. Full results for all 65 gene SNP
sets in the clinically diagnosed AD cohort are shown in
Additional file 1: Table S2. Full results for all 61 gene SNP
sets in the pathologically diagnosed AD cohort are shown
in Additional file 1: Table S3. Together, these results con-
firm our initial findings from the discovery analysis that
rare variants in the exons of TREM2 are enriched in
amnestic AD.
Secondary analysis in clinically heterogeneous AD
Following our discovery and replication analyses, we
conducted an exploratory analysis to identify rare vari-
ants in TREM2 in four clinical variants of AD. We lim-
ited our analysis to UCSF participants. The aggregate
burden p-value for TREM2 across all AD subtypes was
0.044. Of note, in this analysis we identified an add-
itional R136Q mutation in an individual with lvPPA. In
total, we thus identified R136Q in one patient with
lvPPA and in one control in the initial discovery analysis
of amnestic AD. A summary of all variants discovered in
our analyses by diagnostic grouping and cohort is pre-
sented in Additional file 1: Table S4.
Rare TREM2 variants show altered cell surface expression
To characterize the rare TREM2 variants identified in
the UCSF cohort at the protein level, we performed site-
directed mutagenesis on a human TREM2 cDNA. We
restricted our analysis to coding changes affecting the
canonical splice variant of TREM2. For the discovery co-
hort analyses in amnestic and heterogeneous AD, we
generated seven point variants, including those we iden-
tified in amnestic AD (R47H), atypical AD / lvPPA and
controls (R136Q) as well as those identified specifically
in controls (D87N, A130S, R136W, S162R and T223I).
As an internal control for our analyses, we also gener-
ated the Y38C variant involved in early-onset frontotem-
poral dementia (FTD) [32], which is known to be
Table 3 TREM2 SNP-set Characteristics
Cohort CHR BP SNP Minor Allele (+/− strand) AD MAF Control MAF AA change
Discovery (UCSF) 6 41126395 - A/T 0 0.002041 E202D
6 41126619 rs138355759 A/T 0 0.002041 T223I
6 41126801 rs371702633 C/G 0 0.002041 S162R
6 41127605 rs149622783 T/A 0 0.002041 R136Q
6 41127606 - A/T 0 0.002041 R136W
6 41129004 - A/T 0 0.002041 A130S
6 41129133 rs142232675 T/A 0 0.002041 D87N
6 41129252 rs75932628 T/A 0.04839 0 R47H
Replication (ADSP) 6 41126642 - C/G 0.000171 0 H215Q
6 41126701 - T/A 0.000171 0 A196T
6 41126801 rs371702633 C/G 0.000342 0 S162R
6 41127543 rs2234255 A/T 0.00103 0 H157Y
6 41127561 rs79011726 T/A 0.000172 0 E151K
6 41129133 rs142232675 T/A 0.001708 0.0009498 D87N
6 41129195 rs201258663 A/T 0.000171 0 T66M
6 41129252 rs75932628 T/A 0.008944 0.001716 R47H
6 41129253 rs753325601 A/T 0.000172 0 R47C
6 41129295 rs104894002 A/T 0.000345 0 Q33*
6 41129300 rs746216516 A/T 0.000173 0 S31F
6 41129309 rs2234252 A/T 0.000173 0 A28V
6 41129313 rs768745050 T/A 0.000173 0 V27M
6 41129345 rs777808487 A/T 0.000177 0 S16F
Detailed results for TREM2 SNP sets used in discovery and replication analyses. Variants in bold were included in the protein expression experiments. CHR
Chromosome, BP Base Pair, rsID Reference SNP Cluster ID, MAF Minor Allele Frequency, AA Amino Acid
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defective for protein maturation. These variants were
transfected into HEK-293T cells and their expression
analyzed by immunoblotting. All variants other than
Y38C showed apparently normal protein maturation
(Fig. 1a). Interestingly, the immature bands of variants
R136Q and T223I showed slightly altered migration by
SDS-PAGE, with R136Q migrating slightly slower and
T223I slightly faster. Although variant R136Q occasion-
ally showed accumulation of its immature form (Fig. 1a),
we did not observe this effect consistently (Fig. 1b). Be-
cause we identified R136Q in a patient with atypical AD
(as well as in one control), and variants R136Q and
R136W have both been observed in AD cases in other
studies [2, 4, 5], we further characterized these variants.
Of note, R136W has been suggested in unpublished
work [33] to show reduced cell surface expression. Thus,
we performed cell surface biotinylation on cells express-
ing these variants. We observed a modest but statisti-
cally significant reduction in surface expression for
variant R136Q (Fig. 1b, c). In addition, we observed an
even larger defect for R136W, highlighting the import-
ance of residue Arg 136 for normal TREM2 surface ex-
pression levels. Analysis of the overall expression level of
these variants in whole-cell lysates indicated that
R136W was significantly reduced (Fig. 1b, c). Mutation
of residue Arg 136 thus appears capable of altering both
cell surface and overall TREM2 expression.
We next characterized selected variants identified in the
replication cohort, all of which were identified in AD
cases. We focused on variants localizing to the extracellu-
lar domain, as this is the region affected by the R47H vari-
ant as well as many of the NHD-causing mutations in
TREM2. As with the initial set of variants characterized,
we observed apparently normal protein maturation in the
five variants studied (V27M, A28V, S31F, R47C and
E151K; Fig. 2a, left). However, we observed significant re-
ductions in overall expression as well as cell surface ex-
pression for variants S31F and R47C (Fig. 2a, b). Variant
E151K showed reduced overall expression, but its trend
toward reduced surface expression did not reach signifi-
cance. To our knowledge, variant S31F has not been pre-
viously reported as a risk variant in AD and thus is a
novel TREM2 variant for the field. Variant R47C also ap-
pears to be a novel variant and was found in a patient with
pathologically confirmed AD (Braak stage 6). Interestingly,
R47C affects the same arginine residue altered in the
R47H variant. Finally, variant A28V showed a significant
increase in cell surface expression.
A
B C
Fig. 1 Biochemical characterization of rare TREM2 variants identified at the UCSF Memory and Aging Center. a Seven rare TREM2 variants were
transiently expressed in HEK-293T cells and compared to cells expressing wild type (WT) TREM2, the Y38C variant or untransfected cells (—). One
day after transfection, cells were lysed and the lysates analyzed (in duplicate) by immunoblotting for TREM2 to assess expression, maturation, and
electrophoretic mobility. The newly identified variants showed apparently normal maturation, but variant R136Q, identified in a patient with
atypical AD, showed slower migration of the immature band. Clathrin heavy chain (CHC) was used as a loading control. b and c Whole-cell lysate
and cell surface biotinylation analysis for variants R136Q and R136W demonstrate significantly reduced overall expression for variant R136W and
significantly reduced surface expression for both variants (* p < 0.05, *** p < 0.001, **** p < 0.0001 by ANOVA followed by Holm-Sidak post hoc
test). CHC was used a loading control for the cell lysates and to confirm the lack of non-specific biotinylation of cytosolic proteins. Results were
quantified from three independent experiments
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Discussion
We confirmed association of aggregate rare variation in
TREM2 with AD in two independent cohorts, including
in a subset of individuals with pathologically confirmed
AD. Two of the variants identified in AD, S31F and
R47C, have not, to our knowledge, been described be-
fore. In addition, the R136Q variant identified in an
atypical form of AD has not been previously character-
ized at the protein level. Using heterologous expression,
we found that these three variants show a significant re-
duction in cell surface expression relative to WT
TREM2.
Rare homozygous or compound heterozygous muta-
tions in TREM2 cause NHD or an early-onset FTD syn-
drome without bone involvement [8, 34]. These include
missense mutations such as Y38C, T66M and D86V that
occur within the Ig-like domain of TREM2 [32, 35, 36].
Variants Y38C and T66M have been shown to have im-
paired cell surface expression [14, 37], and we now dem-
onstrate that the novel variants S31F and R47C, which
also localize to the Ig-like domain, show reduced surface
expression. Thus, it is possible that modestly reduced
TREM2 cell surface expression in heterozygotes
increases risk for late-onset neurodegeneration, while
severely reduced surface expression in homozygotes
leads to early-onset FTD or NHD. By extension, we
hypothesize that homozygous carriers of S31F, R47C or
R136Q, if identified, might be at greater risk for AD neu-
rodegeneration, relative to heterozygotes. In contrast to
the above variants, variant A28V, which was also identi-
fied in an AD case, showed significantly increased sur-
face expression. It is thus currently unclear if this variant
is impaired in another way (e.g., defective ligand bind-
ing) or if it contributes risk for disease.
In all of our surface expression analyses, we observed
that the immature form of TREM2 was capable of
reaching the cell surface. Although this was reported
previously for disease-causing variants Y38C and T66M,
it was not observed for the WT protein [14]. We specu-
late that this discrepancy may be due to the different ex-
pression systems used (transient expression in this paper
vs. stable expression in [14]). Importantly, however, we
confirmed the strong reduction in surface expression for
variant Y38C that was reported previously in Kleinberger
et al. [14] and Park et al. [37], indicating the suitability
of our expression method for cell surface labeling.
A
B
Fig. 2 Biochemical analysis of additional rare TREM2 variants identified in the Alzheimer’s Disease Sequencing Project (ADSP) replication cohort.
a and b Five additional rare TREM2 variants identified in patients with AD were analyzed as in Fig. 1. All variants showed normal maturation and
mobility by immunoblot analysis. CHC was used as a loading control for the cell lysates and to control for non-specific biotinylation (as above).
Whole-cell lysate and cell surface biotinylation analysis indicated that variants S31F, R47C and E151K showed significantly reduced overall expression,
while S31F and R47C showed significantly reduced surface expression. Variant A28V specifically showed increased surface expression. Variants Y38C
and R47H were used, respectively, as internal controls for severe or modest reductions in cell surface expression (* p < 0.05, ** p < 0.01 by ANOVA
followed by Holm-Sidak post hoc test). Results were quantified from 3–4 independent experiments for each variant
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TREM2 variant R136Q was identified in one patient
with a language-predominant form of AD, the logopenic
variant of primary progressive aphasia (lvPPA, [24]). We
also identified R136Q and R136W in one control each,
underscoring the point that these variants do not appear
to be causative for disease. However, others have pre-
viously reported both of these variants in amnestic AD
[2, 5], and they have MAFs of 0.001278 and 0.0001381,
respectively (2 observations in 1,564 alleles and 1 obser-
vations in 7,240 alleles, respectively) in the Exome Ag-
gregation Consortium (ExAC) database [38]. The
reported MAF of R47H is about 20-fold greater than
that reported for R136Q and is consistent with our ob-
servation of only one case harboring this variant.
We utilized an aggregate variant burden test imple-
mented in the SKAT program to assess the effects of
variation across multiple genes—including TREM2—on
risk for AD. Advantages of this package include that it
makes no assumption about the direction or magnitude
of an effect and its ability to account for both a large
fraction of noncausal variants and causal variant effects
that are in different directions. Some limitations occur
when the number of SNPs required in each set results in
exclusion of candidate genes. Analysis of larger cohorts
with deep resequencing data will be required to expand
coverage of rare variation across more genes.
Our finding that some variants do not alter cell-surface
expression does not preclude these variants from altering
AD risk via other mechanisms. For instance, the V27M
and E151K variants did not show significantly reduced
surface expression, but may be defective for ligand bind-
ing, as has been shown recently for R47H and other vari-
ants [16, 39, 40]. Variant A28V, identified in an AD case
and showing increased surface expression, may increase
risk for disease by adversely affecting ligand binding, or,
alternatively, may not affect risk for disease. Future func-
tional studies such as lipoprotein binding and uptake as-
says will be required to further characterize the effects of
the identified variants. We also identified several variants
in controls that will require further genetic and functional
characterization to determine whether they are likely to
alter disease risk. For example, the D87N variant identified
in both cases and controls in our cohorts, has recently
been shown to display a defect in ligand binding [16] and
may thus represent an AD risk variant.
Our study benefits from the analysis of multiple co-
horts representing both amnestic and atypical forms of
AD, pathological confirmation in a subset of individuals
from the replication cohort, and the ability to assess bio-
chemically the effect of select variants on protein expres-
sion and cell surface expression. Caveats of the study
include a limited number of patients in the discovery
cohort—particularly of atypical AD syndromes—and, as
mentioned above, the limited scope of genes analyzed.
Conclusions
In summary, we find that rare variation in TREM2, in-
cluding two variants within the extracellular Ig-like do-
main, may be associated with risk for AD. Our findings
further suggest that impaired overall and cell surface ex-
pression of TREM2 may contribute to risk for AD. In
addition, since the well-known, AD-associated variant
R47H has been proposed to impair TREM2’s ability to
bind extracellular ligands [12, 39, 40], it will be interest-
ing to determine in the future whether the variants iden-
tified here similarly affect ligand binding. Variants that
reduce surface expression without directly impairing lig-
and binding would be attractive targets for therapeutic
intervention that focuses on restoring TREM2 expres-
sion at the cell surface.
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